Biogen (BIIB)
(Real Time Quote from BATS)
$208.01 USD
+5.55 (2.74%)
Updated Apr 26, 2024 12:07 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Biogen Inc. [BIIB]
Reports for Purchase
Showing records 81 - 100 ( 789 total )
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Commercial Biotech Preview: Let''s Get It Started
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 4/7/23
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 41123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 3/31/23
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 4123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Importance of Real World Evidence in Drug Approvals-Insights From AD/PD 2023 Gothenburg
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 3/17/23
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Win for Surrogate Biomarkers in CNS diseases-Broader Implications
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 32123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 3/10/23
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 31123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 3/3/23
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 3123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BIIB 22123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 2/10/23
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Full Potential of Leqembi Might Need Rapid Development of Blood-Based Biomarkers; Reit. Buy and $325 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A